Skip to main content

Advertisement

SpringerLink
Log in

Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration

  • Medical Ophthalmology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the plasma levels of amyloid beta (Aβ) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity.

Methods

Plasma samples were obtained from AMD subjects at various stages of disease—early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)—and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (Aβ isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables.

Results

Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of Αβ isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma Aβ 1–42 levels, and its ratio with Aβ 1–40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for Αβ isotypes, the ROC curve showed a moderate prediction (AUC = - ~ 0.78) of AMD vs control using the Aβ 1−42 isotype.

Conclusion

Plasma Aβ 1–42 may have utility as a systemic biomarker for AMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty L et al (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102(20):7227–7232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ et al (2006) Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 38(9):1055–1059

    Article  CAS  PubMed  Google Scholar 

  3. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al (2004) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385–389

    Article  Google Scholar 

  4. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH (2010) C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 117(10):1982–1928

    Article  PubMed  Google Scholar 

  5. Thakkinstain A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K et al (2006) Systemic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 15(18):2784–2790

    Article  Google Scholar 

  6. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AH, Gehrs K et al (2006) Variation in factor B(BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38(4):458–462

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H et al (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357(6):553–561

    Article  CAS  PubMed  Google Scholar 

  8. Barid PN, Islam FM, Richardson ASH, Cain M, Hunt N, Guymer R (2006) Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest Ophthalmol Vis Sci 47(10):4194–4198

    Article  Google Scholar 

  9. Baird PN, Robman LD, Richardson AJ, Dimitrov PN, Tikellis G, McCarty CA et al (2008) Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 17(9):1299–1305

    Article  CAS  PubMed  Google Scholar 

  10. Mullins RF, Russell SR, Anderson DH, Hageman GS (2000) Drusen associated with age and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14(7):835–846

    CAS  PubMed  Google Scholar 

  11. Johnson LV, Leitner WP, Staples MK, Anderson DH (2001) Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 73(6):887–896

    Article  CAS  PubMed  Google Scholar 

  12. Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134(3):411–431

    Article  CAS  PubMed  Google Scholar 

  13. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johson LV (2004) Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78(2):243–256

    Article  CAS  PubMed  Google Scholar 

  14. Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA (2003) Apolipoprotein B in cholesterol-containing drusen and basal deposits in human eyes with age-related maculopathy. Am J Pathol 162(2):413–425

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL (2003) Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9:184–190

    CAS  PubMed  Google Scholar 

  16. Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28(5):348–368

    Article  PubMed  Google Scholar 

  17. Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de John PT (2007) C-reactive protein level and risk of aging macula disorder: the Rotterdam Study. Arch Ophthalmol 125(10):1396–1401

    Article  CAS  PubMed  Google Scholar 

  18. Klein R, Klein BE, Knudtson MD, Wong TY, Shankar A, Tsai MY (2005) Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol 140(1):35–44

    CAS  PubMed  Google Scholar 

  19. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B et al (2008) Systemic complement activation in age-related macular degeneration. PLOS ONE. doi:10.1371/jornal.pone.0002593

    PubMed  Google Scholar 

  20. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N (2004) Association between C-reactive protein and age-related macular degeneration. JAMA 291(6):704–710

    Article  CAS  PubMed  Google Scholar 

  21. Seddon JM, George S, Rosner B, Rifai N (2005) Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 123(6):774–782

    Article  PubMed  Google Scholar 

  22. KH W, Tan AG, Rochtchina E, Favaloro EJ, Williams A, Mitchell P et al (2007) Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case–control study. Invest Ophthalmol Vis Sci 48(5):1983–1988

    Article  Google Scholar 

  23. Ohno-Matsui K (2011) Parallel findings in age-related macular degeneration and Alzheimers disease. Prog Retin Eye Res 30:217–238

    Article  PubMed  Google Scholar 

  24. Tzekov R, Mullan M (2014) Vision function abnormalities in Alzheimer disease. Surv Ophthalmol 59:414–433

    Article  PubMed  Google Scholar 

  25. Clemons TE, Rankin MW, McBee WL (2006) Cognitive impairment in the age-related eye disease study: AREDS report no. 16. Arch Ophthalmol 124(4):537–543

    Article  PubMed  Google Scholar 

  26. Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT (1999) Is age-related maculopathy associated with Alzheimer’s disease? The Rotterdam Study. Am J Epidemiol 150(9):963–968

    Article  CAS  PubMed  Google Scholar 

  27. Zetterberg M, Landgren S, Andersson ME, Palmer MS, Gustafson DR, Skoog I et al (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147B(6):720–726

    Article  CAS  PubMed  Google Scholar 

  28. Jonson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer’s A beta peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99(18):11930–11935

    Article  Google Scholar 

  29. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med 188(3):431–438

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Wang J, Ohno-Matsui K, Yoshida T, Kojima A, Shimada N, Nakahama K et al (2008) Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from drusen. J Immunol 181(1):712–720

    Article  CAS  PubMed  Google Scholar 

  31. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 57(1):100–105

    Article  CAS  PubMed  Google Scholar 

  32. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol 39(5):367–374

    Article  CAS  PubMed  Google Scholar 

  33. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM (2009) Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50(12):5818–5827

    Article  PubMed Central  PubMed  Google Scholar 

  34. Shankar A, Mitchell P, Rochchina E, Tan J, Wang JJ (2007) Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Am J Epidemiol 165(4):375–382

    Article  PubMed  Google Scholar 

  35. Despriet DD, Klaver CC, Witterman JC, Bergen AA, Kardys I, de Matt MP et al (2006) Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 296(3):301–309

    Article  PubMed  Google Scholar 

  36. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM (2007) High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 125(3):300–305

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Vine AK, Stader J, Branham K, Musch DC, Swaroop A (2005) Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 112(12):2076–2080

    Article  PubMed  Google Scholar 

  38. McGwin G, Hall TA, Xie A, Owsley C (2005) The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol 89(9):1166–1170

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR et al (2007) Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 125(4):515–519

    Article  CAS  PubMed  Google Scholar 

  40. Bibl M, Welge V, Esselmann H, Wiltfang J (2012) Stability of amyloid-beta peptides in plasma and serum. Electrophoresis 33(3):445–450

    Article  CAS  PubMed  Google Scholar 

  41. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61(9):1185–1190

    Article  CAS  PubMed  Google Scholar 

  42. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73(11):847–853

    Article  CAS  PubMed  Google Scholar 

  43. Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR (2008) Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8):596–606

    Article  CAS  PubMed  Google Scholar 

  44. Ding JD, Lin J, Mace BE, Herrman R, Sullivan P, Bowes RC (2008) Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 48(3):339–345

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M et al (2011) Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A 108(28):E279–E287

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, VIC, 3002, Australia

    Robyn Guymer, Tania Cipriani, Lyndell Lim & Liubov D. Robman

  2. Pfizer Inc., 10777 Science Center, San Diego, CA, 92121, USA

    Wenlin Li, Wenlian Wang & Shibing Deng

  3. Bayer Healthcare, 100 Bayer Boulevard, Whippany, NJ, 07981, USA

    Kay D. Rittenhouse

  4. Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd., Tarrytown, NY, 10591, USA

    Poulabi Banerjee

Authors
  1. Robyn Guymer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tania Cipriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kay D. Rittenhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lyndell Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liubov D. Robman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenlin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenlian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shibing Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Poulabi Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robyn Guymer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guymer, R., Cipriani, T., Rittenhouse, K.D. et al. Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253, 1347–1354 (2015). https://doi.org/10.1007/s00417-015-2970-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-2970-x

Keywords

Search

Navigation